ATTO — Attovia Therapeutics, Inc.
$13.83-4.62%
Last close: · regular session
Last 10 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ATTO in the TickerWise workspace.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 44
- Website: https://www.attovia.com
Latest SEC filings for ATTO
- 3/A
- 3/A
- SCHEDULE 13G
- SCHEDULE 13D
- 3
- 3
- 3
- 3
- EFFECT
- S-1/A
Latest ATTO news
- Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.